Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The most common adverse reactions occurring in greater than 10 percent of patients receiving Endari in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain, and chest pain.

Endari should only be taken under the direction of a physician. Endari has received Orphan Drug designation in the U.S. and Orphan Medicinal Product designation in the EU.